REFERENCES
1. Leow MK. Environmental origins of hypertension: phylogeny, ontogeny and epigenetics. Hypertens Res 2015;38:299-307.
2. Beevers G, Lip GY, O’Brien E. ABC of hypertension: the pathophysiology of hypertension. BMJ 2001;322:912-6.
5. Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension 2020;75:285-92.
6. Roth GA, Mensah GA, Johnson CO, et al. GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol 2020;76:2982-3021.
7. Kamali Z, Keaton JM, Haghjooy Javanmard S, et al. Large-scale multi-omics studies provide new insights into blood pressure regulation. Int J Mol Sci 2022;23:7557.
8. Dinakis E, Nakai M, Gill P, et al. Association between the gut microbiome and their metabolites with human blood pressure variability. Hypertension 2022;79:1690-701.
9. Adua E. Decoding the mechanism of hypertension through multiomics profiling. J Hum Hypertens 2023;37:253-64.
11. Nitzan M, Nitzan I. Feasibility of precision medicine in hypertension management-scope and technological aspects. J Pers Med 2022;12:1861.
12. Linares DM, Ross P, Stanton C. Beneficial microbes: the pharmacy in the gut. Bioengineered 2016;7:11-20.
13. Eloe-Fadrosh EA, Rasko DA. The human microbiome: from symbiosis to pathogenesis. Annu Rev Med 2013;64:145-63.
14. Sudhakar P, Machiels K, Verstockt B, Korcsmaros T, Vermeire S. Computational biology and machine learning approaches to understand mechanistic microbiome-host interactions. Front Microbiol 2021;12:618856.
15. Grazioli F, Siarheyeu R, Alqassem I, Henschel A, Pileggi G, Meiser A. Microbiome-based disease prediction with multimodal variational information bottlenecks. PLoS Comput Biol 2022;18:e1010050.
16. Palmu J, Lahti L, Niiranen T. Targeting gut microbiota to treat hypertension: a systematic review. Int J Environ Res Public Health 2021;18:1248.
17. Aryal S, Manandhar I, Mei X, et al. Combating hypertension beyond GWAS: microbiome and artificial intelligence as opportunities for precision medicine. Camb Prisms Precis Med 2023;1:e26.
18. Nakai M, Ribeiro RV, Stevens BR, et al. Essential hypertension is associated with changes in gut microbial metabolic pathways: a multisite analysis of ambulatory blood pressure. Hypertension 2021;78:804-15.
19. Pontarollo G, Kollar B, Mann A, et al. Commensal bacteria weaken the intestinal barrier by suppressing epithelial neuropilin-1 and Hedgehog signaling. Nat Metab 2023;5:1174-87.
20. Lecuit M, Eloit M. Chapter 21 - The viruses of the gut microbiota. In: The microbiota in gastrointestinal pathophysiology. Elsevier; 2017. pp. 179-83.
22. Beam A, Clinger E, Hao L. Effect of diet and dietary components on the composition of the gut microbiota. Nutrients 2021;13:2795.
23. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ 2018;361:k2179.
24. Guinane CM, Cotter PD. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Therap Adv Gastroenterol 2013;6:295-308.
25. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol 2015;21:8787-803.
26. Wu Y, Xu H, Tu X, Gao Z. The role of short-chain fatty acids of gut microbiota origin in hypertension. Front Microbiol 2021;12:730809.
27. Chen XF, Ren SC, Tang G, Wu C, Chen X, Tang XQ. Short-chain fatty acids in blood pressure, friend or foe. Chin Med J 2021;134:2393-4.
28. Miyamoto J, Kasubuchi M, Nakajima A, Irie J, Itoh H, Kimura I. The role of short-chain fatty acid on blood pressure regulation. Curr Opin Nephrol Hypertens 2016;25:379-83.
29. Huynh K. Microbial metabolites reduce SBP in patients with resistant hypertension. Nat Rev Cardiol 2023;20:140.
30. Deng W, Zhang L, Du Q, et al. The association of serum total bile acid with new-onset hypertension during pregnancy. BMC Pregnancy Childbirth 2022;22:879.
32. O’Donnell JA, Zheng T, Meric G, Marques FZ. The gut microbiome and hypertension. Nat Rev Nephrol 2023;19:153-67.
33. Avery EG, Bartolomaeus H, Maifeld A, et al. The gut microbiome in hypertension: recent advances and future perspectives. Circ Res 2021;128:934-50.
34. Yan D, Sun Y, Zhou X, et al. Regulatory effect of gut microbes on blood pressure. Animal Model Exp Med 2022;5:513-31.
36. Song JS, Kim JOR, Yoon SM, Kwon M, Ki C. The association between gut microbiome and hypertension varies according to enterotypes: a Korean study. Front Microbiomes 2023;2:1072059.
37. Zhang Y, Zheng T, Ma D, et al. Probiotics Bifidobacterium lactis M8 and Lactobacillus rhamnosus M9 prevent high blood pressure via modulating the gut microbiota composition and host metabolic products. mSystems 2023;8:e0033123.
38. Cookson TA. Bacterial-induced blood pressure reduction: mechanisms for the treatment of hypertension via the gut. Front Cardiovasc Med 2021;8:721393.
39. Hoyles L, Jiménez-Pranteda ML, Chilloux J, et al. Metabolic retroconversion of trimethylamine N-oxide and the gut microbiota. Microbiome 2018;6:73.
40. Shanmugham M, Bellanger S, Leo CH. Gut-derived metabolite, trimethylamine-N-oxide (TMAO) in cardio-metabolic diseases: detection, mechanism, and potential therapeutics. Pharmaceuticals 2023;16:504.
41. Huang R, Yan L, Lei Y. The gut microbial-derived metabolite trimethylamine N-oxide and atrial fibrillation: relationships, mechanisms, and therapeutic strategies. Clin Interv Aging 2021;16:1975-86.
42. Yang S, Li X, Yang F, et al. Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target. Front Pharmacol 2019;10:1360.
43. Khodor S, Reichert B, Shatat IF. The microbiome and blood pressure: can microbes regulate our blood pressure? Front Pediatr 2017;5:138.
44. Masenga SK, Hamooya B, Hangoma J, et al. Recent advances in modulation of cardiovascular diseases by the gut microbiota. J Hum Hypertens 2022;36:952-9.
45. Jama HA, Kaye DM, Marques FZ. The gut microbiota and blood pressure in experimental models. Curr Opin Nephrol Hypertens 2019;28:97-104.
46. Joe B, McCarthy CG, Edwards JM, et al. Microbiota introduced to germ-free rats restores vascular contractility and blood pressure. Hypertension 2020;76:1847-55.
47. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res 2020;30:492-506.
48. Krzemińska J, Wronka M, Młynarska E, Franczyk B, Rysz J. Arterial hypertension-oxidative stress and inflammation. Antioxidants 2022;11:172.
49. Ghatage T, Goyal SG, Dhar A, Bhat A. Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies. Hypertens Res 2021;44:740-55.
50. Prado NJ, Ramirez D, Mazzei L, et al. Anti-inflammatory, antioxidant, antihypertensive, and antiarrhythmic effect of indole-3-carbinol, a phytochemical derived from cruciferous vegetables. Heliyon 2022;8:e08989.
51. Tokarek J, Budny E, Saar M, et al. Does the composition of gut microbiota affect hypertension? Molecular mechanisms involved in increasing blood pressure. Int J Mol Sci 2023;24:1377.
52. Sun D, Xiang H, Yan J, He L. Intestinal microbiota: a promising therapeutic target for hypertension. Front Cardiovasc Med 2022;9:970036.
53. Caspani G, Kennedy S, Foster JA, Swann J. Gut microbial metabolites in depression: understanding the biochemical mechanisms. Microb Cell 2019;6:454-81.
54. Parker A, Fonseca S, Carding SR. Gut microbes and metabolites as modulators of blood-brain barrier integrity and brain health. Gut Microbes 2020;11:135-57.
55. Zheng T, Marques FZ. Gut microbiota: friends or foes for blood pressure-lowering drugs. Hypertension 2022;79:1602-4.
56. Chen HQ, Gong JY, Xing K, Liu MZ, Ren H, Luo JQ. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in antihypertensive treatment. Front Med 2021;8:742394.
57. Faselis C, Doumas M, Papademetriou V. Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens 2011;2011:236239.
58. Kyoung J, Atluri RR, Yang T. Resistance to antihypertensive drugs: is gut microbiota the missing link? Hypertension 2022;79:2138-47.
59. Choi MS, Yu JS, Yoo HH, Kim DH. The role of gut microbiota in the pharmacokinetics of antihypertensive drugs. Pharmacol Res 2018;130:164-71.
60. Qi Y, Aranda JM, Rodriguez V, Raizada MK, Pepine CJ. Impact of antibiotics on arterial blood pressure in a patient with resistant hypertension - a case report. Int J Cardiol 2015;201:157-8.
61. Robles-Vera I, Toral M, de la Visitación N, et al. Changes to the gut microbiota induced by losartan contributes to its antihypertensive effects. Br J Pharmacol 2020;177:2006-23.
62. Karbach SH, Schönfelder T, Brandão I, et al. Gut microbiota promote angiotensin II-induced arterial hypertension and vascular dysfunction. J Am Heart Assoc 2016;5:e003698.
63. Yang T, Aquino V, Lobaton GO, et al. Sustained captopril-induced reduction in blood pressure is associated with alterations in gut-brain axis in the spontaneously hypertensive rat. J Am Heart Assoc 2019;8:e010721.
64. Brocker CN, Velenosi T, Flaten HK, et al. Metabolomic profiling of metoprolol hypertension treatment reveals altered gut microbiota-derived urinary metabolites. Hum Genomics 2020;14:10.
65. Konop M, Radkowski M, Grochowska M, Perlejewski K, Samborowska E, Ufnal M. Enalapril decreases rat plasma concentration of TMAO, a gut bacteria-derived cardiovascular marker. Biomarkers 2018;23:380-5.
66. Unger T, Borghi C, Charchar F, et al. 2020 international society of hypertension global hypertension practice guidelines. Hypertension 2020;75:1334-57.
67. Davani-Davari D, Negahdaripour M, Karimzadeh I, et al. Prebiotics: definition, types, sources, mechanisms, and clinical applications. Foods 2019;8:92.
68. Jama HA, Rhys-Jones D, Nakai M, et al. Prebiotic intervention with HAMSAB in untreated essential hypertensive patients assessed in a phase II randomized trial. Nat Cardiovasc Res 2023;2:35-43.
69. Streppel MT, Arends LR, van ’t Veer P, Grobbee DE, Geleijnse JM. Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch Intern Med 2005;165:150-6.
70. Ansari F, Neshat M, Pourjafar H, Jafari SM, Samakkhah SA, Mirzakhani E. The role of probiotics and prebiotics in modulating of the gut-brain axis. Front Nutr 2023;10:1173660.
71. Khalesi S, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension 2014;64:897-903.
72. Qi D, Nie XL, Zhang JJ. The effect of probiotics supplementation on blood pressure: a systemic review and meta-analysis. Lipids Health Dis 2020;19:79.
73. Cardoso AM. Can changes in gut microbiota predict progression toward diabetes? J Explor Res Pharmacol 2021;6:168-9.
